Imagine a world where hearing loss could be reversed, not just managed. That's the bold vision driving a groundbreaking partnership between Shionogi & Co., Ltd. and Salubritas Therapeutics. In a move that could revolutionize the treatment of hearing impairment, these two companies have joined forces to tackle one of the most challenging medical puzzles of our time: regenerating the delicate hair cells in the inner ear responsible for hearing. But here's where it gets controversial: while hearing aids and cochlear implants have been the standard solutions, this collaboration aims to go beyond symptom management and address the root cause of hearing loss. And this is the part most people miss: the potential for a pharmaceutical solution that could restore hearing function by regenerating these crucial cells.
OSAKA, Japan, December 23, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), a leader in innovative healthcare solutions, has announced a joint research and development (R&D) and investment agreement with Salubritas Therapeutics (Head Office: Massachusetts, USA; Chief Executive Officer: En Li, Ph.D.). This partnership is focused on a transformative goal: demonstrating the improvement of hearing function through the regeneration of sensory hair cells in the inner ear and developing cutting-edge pharmaceuticals. This ambitious endeavor seeks to address the growing global crisis of hearing loss, which currently affects an estimated 1.5 billion people worldwide—a number projected to rise dramatically, with a quarter of the global population expected to experience hearing impairment by 2050.
Why is this so challenging? Hair cell regeneration is considered a holy grail in audiology, offering a potential cure for sensorineural hearing loss, which has no effective treatments beyond hearing aids and cochlear implants. However, despite its promise, no clinical trials have successfully demonstrated hair cell regeneration, and drug discovery in this field is notoriously difficult. Shionogi and Salubritas aim to change that by combining Shionogi’s commitment to innovative treatments with Salubritas’ cutting-edge expertise in hair cell regeneration technology. Together, they hope to develop a therapeutic drug that not only regenerates hair cells but also restores hearing function, offering new hope to millions.
The stakes are high. Hearing loss is more than just a medical condition; it’s a social and cognitive challenge. It impairs communication, isolates individuals, and is linked to serious health risks, including dementia. Yet, the slow progression of hearing loss often makes it difficult to diagnose early, leaving many without timely intervention. This partnership represents a beacon of hope, but it also raises questions: Can pharmaceutical solutions truly outperform existing devices? And what ethical considerations arise if such a treatment becomes a reality? We invite you to share your thoughts in the comments.
About Salubritas
Founded in 2021, Salubritas Therapeutics is at the forefront of hearing loss research, focusing on regenerative therapies for sensory hair cells. The company’s co-founder, Dr. Zheng-Yi Chen, an Associate Professor at Mass Eye and Ear and Harvard Medical School, made history by becoming the first to successfully differentiate and induce hair cells from somatic cells in adult animals without using pluripotent stem cells. This breakthrough positions Salubritas as a pioneer in the field, with a strong network of collaborations, including Massachusetts Eye and Ear, a global leader in otology and inner ear disease research. Their goal? To develop treatments that regenerate functional hair cells, potentially restoring hearing for those affected.
About Hearing Loss
Hearing loss is a silent epidemic, exacerbated by an aging global population and often overlooked due to its gradual onset. Beyond the obvious communication barriers, it’s a risk factor for central nervous system disorders, including dementia. While hearing aids and cochlear implants provide relief, they don’t address the underlying cause. This is why the prospect of hair cell regeneration is so exciting—it could offer a cure, not just a workaround. But is society ready for such a paradigm shift? Let us know your thoughts.
References
1. WORLD REPORT ON HEARING, WHO, 2021. https://www.who.int/teams/noncommunicable-diseases/sensory-functions-disability-and-rehabilitation/highlighting-priorities-for-ear-and-hearing-care
2. GBD 2019 Hearing Loss Collaborators. Lancet. 2021; 397: 996-1009. https://pubmed.ncbi.nlm.nih.gov/33714390/
3. Wu, Pei-zhe, et al. Journal of Neuroscience. 2020; 40: 6357-6366. https://pubmed.ncbi.nlm.nih.gov/32690619/
4. Quan Yi-Zhou, et al. Proc Natl Acad Sci U.S.A. 2023; 120: e2215253120. https://pubmed.ncbi.nlm.nih.gov/37068229/
5. Livingston Gill, et al. Lancet. 2024; 404: 572-628. https://pubmed.ncbi.nlm.nih.gov/39096926/
Forward-Looking Statements
This announcement includes forward-looking statements based on current expectations and assumptions, which are subject to risks and uncertainties. Factors such as economic conditions, industry trends, regulatory changes, and clinical trial outcomes could cause actual results to differ materially. Shionogi disclaims any obligation to update these statements in light of new information or future events.
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
